Roles of estrogen receptor α in endometrial carcinoma (Review).

Yidong Ge, Xiaoqi Ni, Jingyun Li, Meng Ye, Xiaofeng Jin
Author Information
  1. Yidong Ge: Department of Medical Oncology, The First Hospital of Ningbo University, Ningbo University, Ningbo, Zhejiang 315020, P.R. China.
  2. Xiaoqi Ni: Department of Medical Oncology, The First Hospital of Ningbo University, Ningbo University, Ningbo, Zhejiang 315020, P.R. China.
  3. Jingyun Li: Department of Medical Oncology, The First Hospital of Ningbo University, Ningbo University, Ningbo, Zhejiang 315020, P.R. China.
  4. Meng Ye: Department of Medical Oncology, The First Hospital of Ningbo University, Ningbo University, Ningbo, Zhejiang 315020, P.R. China.
  5. Xiaofeng Jin: Department of Medical Oncology, The First Hospital of Ningbo University, Ningbo University, Ningbo, Zhejiang 315020, P.R. China.

Abstract

Endometrial carcinoma (EC) is a group of endometrial epithelial malignancies, most of which are adenocarcinomas and occur in perimenopausal and postmenopausal women. It is one of the most common carcinomas of the female reproductive system. It has been shown that the occurrence and development of EC is closely associated with the interaction between estrogen (estradiol, E2) and estrogen receptors (ERs), particularly ERα. As a key nuclear transcription factor, ERα is a carcinogenic factor in EC. Its interactions with upstream and downstream effectors and co-regulators have important implications for the proliferation, metastasis, invasion and inhibition of apoptosis of EC. In the present review, the structure of ERα and the regulation of ERα in multiple dimensions are described. In addition, the classical E2/ERα signaling pathway and the crosstalk between ERα and other EC regulators are elucidated, as well as the therapeutic targeting of ERα, which may provide a new direction for clinical applications of ERα in the future.

Keywords

References

  1. Clin Cancer Res. 2016 Aug 15;22(16):4215-24 [PMID: 27006490]
  2. J Neuroinflammation. 2018 Jul 12;15(1):206 [PMID: 30001721]
  3. PLoS One. 2014 Jan 31;9(1):e87563 [PMID: 24498137]
  4. Reprod Sci. 2008 Dec;15(10):1011-7 [PMID: 19088370]
  5. Cancer Lett. 2016 Jun 28;376(1):127-36 [PMID: 27018308]
  6. Front Oncol. 2019 May 07;9:359 [PMID: 31134155]
  7. Gynecol Oncol. 2021 Feb;160(2):579-585 [PMID: 33276986]
  8. Science. 1995 Dec 1;270(5241):1491-4 [PMID: 7491495]
  9. Mol Cancer Ther. 2005 Aug;4(8):1239-49 [PMID: 16093440]
  10. J Pathol. 2008 Oct;216(2):151-7 [PMID: 18720455]
  11. Int J Gynecol Cancer. 2012 Nov;22(9):1509-16 [PMID: 23051957]
  12. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1316-E1325 [PMID: 28167798]
  13. J Obstet Gynaecol Res. 2008 Aug;34(4):567-73 [PMID: 18937711]
  14. Pathol Res Pract. 2020 Oct;216(10):153149 [PMID: 32853964]
  15. J Mol Med (Berl). 2013 Feb;91(2):249-59 [PMID: 22926011]
  16. Cancer Lett. 2012 Jan 1;314(1):41-53 [PMID: 21983130]
  17. Cancer Sci. 2005 Oct;96(10):645-52 [PMID: 16232195]
  18. Oncol Rep. 2010 Aug;24(2):385-93 [PMID: 20596625]
  19. Cureus. 2021 Nov 30;13(11):e20030 [PMID: 34987915]
  20. J Biol Chem. 1998 May 15;273(20):12101-8 [PMID: 9575154]
  21. Cancer Res. 2006 Apr 1;66(7):3375-80 [PMID: 16585156]
  22. Mol Cell Endocrinol. 2011 Oct 15;345(1-2):27-37 [PMID: 21784129]
  23. Cancer Res. 2007 Aug 15;67(16):7746-55 [PMID: 17699779]
  24. Clin Cancer Res. 2008 Aug 15;14(16):5000-5 [PMID: 18698017]
  25. Adv Protein Chem Struct Biol. 2019;116:135-170 [PMID: 31036290]
  26. J Biol Chem. 2023 Jan;299(1):102734 [PMID: 36423684]
  27. Oncol Rep. 2019 Mar;41(3):1575-1585 [PMID: 30569100]
  28. Mol Endocrinol. 2007 Dec;21(12):2988-3001 [PMID: 17717078]
  29. Endocrine. 2008 Feb;33(1):1-8 [PMID: 18363044]
  30. J Biol Chem. 2019 Dec 20;294(51):19667-19682 [PMID: 31744881]
  31. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [PMID: 17826626]
  32. Cancer Biol Ther. 2015;16(4):493-7 [PMID: 25719413]
  33. Mol Cell Endocrinol. 2001 Feb 14;172(1-2):223-33 [PMID: 11165056]
  34. Fertil Steril. 2006 Aug;86(2):469-72 [PMID: 16730717]
  35. Carcinogenesis. 2001 Nov;22(11):1809-17 [PMID: 11698343]
  36. Cancer Cell Int. 2014 Dec 20;14(1):540 [PMID: 25663821]
  37. Mol Endocrinol. 2006 May;20(5):971-83 [PMID: 16410316]
  38. Cancer Res. 2011 Mar 1;71(5):1584-96 [PMID: 21363919]
  39. Arch Med Sci. 2017 Mar 1;13(2):293-301 [PMID: 28261281]
  40. Biochem Biophys Res Commun. 2017 Jul 22;489(2):96-102 [PMID: 28528974]
  41. Gynecol Oncol. 1999 Jul;74(1):38-47 [PMID: 10385549]
  42. Cancer Res. 2020 Mar 15;80(6):1234-1245 [PMID: 32046982]
  43. Int J Cancer. 2014 Jul 15;135(2):282-94 [PMID: 24347287]
  44. Cancer Res. 2003 Oct 1;63(19):6195-9 [PMID: 14559803]
  45. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):843-5 [PMID: 15573770]
  46. Cell Death Dis. 2018 Dec 18;10(1):4 [PMID: 30584245]
  47. Tumour Biol. 2014 Dec;35(12):11939-47 [PMID: 25182852]
  48. J Steroid Biochem Mol Biol. 2018 Feb;176:4-15 [PMID: 28347854]
  49. Essays Biochem. 2021 Dec 17;65(6):867-875 [PMID: 34028522]
  50. Toxicol Appl Pharmacol. 2005 Dec 15;209(3):226-35 [PMID: 15922381]
  51. Oncol Rep. 2014 Mar;31(3):1225-34 [PMID: 24452315]
  52. Oncol Lett. 2021 Jan;21(1):20 [PMID: 33240426]
  53. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  54. J Biomol Struct Dyn. 2022 Jul;40(11):5203-5210 [PMID: 33402049]
  55. Gynecol Oncol. 2001 Jun;81(3):366-72 [PMID: 11371124]
  56. Pathol Int. 2005 Nov;55(11):707-15 [PMID: 16271083]
  57. Cell Signal. 2017 Jun;34:121-132 [PMID: 28341599]
  58. BMC Cancer. 2008 Nov 06;8:322 [PMID: 18990228]
  59. Steroids. 2018 May;133:34-37 [PMID: 29122548]
  60. Endocr Relat Cancer. 2020 Feb;27(2):55-66 [PMID: 31778358]
  61. Mod Pathol. 2015 Jun;28(6):836-44 [PMID: 25720322]
  62. J BUON. 2013 Apr-Jun;18(2):465-70 [PMID: 23818363]
  63. Clin Cancer Res. 2013 Mar 1;19(5):1094-105 [PMID: 23319822]
  64. Chem Phys Lipids. 2013 Oct-Nov;175-176:27-32 [PMID: 23954748]
  65. Gynecol Endocrinol. 2011 Aug;27(8):536-40 [PMID: 21726118]
  66. Zhonghua Yi Xue Za Zhi. 2007 Jul 17;87(27):1900-3 [PMID: 17923013]
  67. Eur Endocrinol. 2013 Mar;9(1):18-21 [PMID: 30349605]
  68. Anticancer Res. 2013 Sep;33(9):3775-81 [PMID: 24023309]
  69. Int J Gynecol Cancer. 2011 Feb;21(2):194-202 [PMID: 21270601]
  70. Fertil Steril. 2011 Feb;95(2):722-6 [PMID: 20869705]
  71. Mol Pharmacol. 2016 Jan;89(1):14-26 [PMID: 26487511]
  72. Virchows Arch. 2008 Dec;453(6):557-69 [PMID: 18853184]
  73. Oncol Rep. 2014 Mar;31(3):1175-82 [PMID: 24366110]
  74. Balkan Med J. 2021 Jan;38(1):7-12 [PMID: 33593716]
  75. Gynecol Oncol. 2014 Nov;135(2):184-9 [PMID: 25173583]
  76. J Clin Invest. 2010 Jul;120(7):2319-30 [PMID: 20577047]
  77. Nat Rev Endocrinol. 2011 Aug 16;7(12):715-26 [PMID: 21844907]
  78. Cell Death Dis. 2015 Mar 12;6:e1687 [PMID: 25766326]
  79. Mol Pharmacol. 2005 Dec;68(6):1852-62 [PMID: 16186250]
  80. Front Oncol. 2020 Aug 26;10:1509 [PMID: 32983995]
  81. Pathol Res Pract. 2022 Mar;231:153795 [PMID: 35134625]
  82. J Cell Physiol. 2006 Aug;208(2):255-66 [PMID: 16688764]
  83. J Pathol. 2008 Nov;216(3):271-4 [PMID: 18788074]
  84. Gynecol Oncol. 2004 Jan;92(1):304-13 [PMID: 14751175]
  85. Biomed Res Int. 2014;2014:713263 [PMID: 25221777]
  86. J Clin Oncol. 2005 Aug 1;23(22):5108-16 [PMID: 15998903]
  87. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):231-7 [PMID: 21888973]
  88. Mol Cell Endocrinol. 2016 Jun 15;428:142-7 [PMID: 27033325]
  89. J Clin Oncol. 2012 Aug 1;30(22):2718-24 [PMID: 22565002]
  90. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:193-206 [PMID: 25917453]
  91. Cancer Lett. 2012 Jun 1;319(1):89-97 [PMID: 22222214]
  92. Cancer Lett. 2019 Feb 1;442:137-147 [PMID: 30420335]
  93. Reprod Sci. 2015 Feb;22(2):146-55 [PMID: 25258361]
  94. Eur J Gynaecol Oncol. 2007;28(2):89-94 [PMID: 17479667]
  95. Diagn Pathol. 2014 Mar 31;9:77 [PMID: 24684970]
  96. J Cell Sci. 2010 Apr 15;123(Pt 8):1253-61 [PMID: 20332105]
  97. Nat Rev Cancer. 2019 Sep;19(9):510-521 [PMID: 31388127]
  98. Pathol Oncol Res. 2005;11(1):32-9 [PMID: 15800680]
  99. Gynecol Oncol. 2009 Mar;112(3):537-42 [PMID: 19108875]
  100. Int J Gynecol Cancer. 2014 Jan;24(1):102-6 [PMID: 24335662]
  101. PLoS One. 2013 Jul 09;8(7):e68075 [PMID: 23874500]
  102. Anticancer Res. 2002 Nov-Dec;22(6C):3993-4003 [PMID: 12553024]
  103. Immunol Cell Biol. 2019 Jul;97(6):563-576 [PMID: 30779215]
  104. Pathol Oncol Res. 2020 Jul;26(3):1411-1416 [PMID: 31811476]
  105. BMC Cancer. 2015 Feb 27;15:86 [PMID: 25884434]
  106. Mol Endocrinol. 2005 Nov;19(11):2671-84 [PMID: 15961505]
  107. Mol Biol Rep. 2021 Nov;48(11):7517-7526 [PMID: 34657250]
  108. Cell Physiol Biochem. 2018;50(2):706-720 [PMID: 30308493]
  109. J Cell Mol Med. 2014 May;18(5):863-74 [PMID: 24495253]
  110. Nutrients. 2018 May 25;10(6): [PMID: 29799481]
  111. Anticancer Res. 2005 May-Jun;25(3A):1679-86 [PMID: 16033082]
  112. J Oncol. 2019 Dec 24;2019:7252013 [PMID: 31929798]
  113. Cancer Lett. 2012 Jan 28;314(2):155-65 [PMID: 22014978]
  114. Mol Nutr Food Res. 2016 Nov;60(11):2387-2395 [PMID: 27342949]
  115. Biochem Biophys Res Commun. 2019 Feb 5;509(2):541-548 [PMID: 30598260]
  116. Biochem Pharmacol. 2009 Feb 15;77(4):474-84 [PMID: 18838062]
  117. J Biol Chem. 2009 Jun 12;284(24):16135-16145 [PMID: 19383985]
  118. Onco Targets Ther. 2019 Aug 20;12:6757-6767 [PMID: 31686835]
  119. Am J Obstet Gynecol. 2011 Sep;205(3):227.e1-6 [PMID: 21684519]
  120. Reprod Sci. 2019 May;26(5):609-618 [PMID: 29848180]
  121. J Pathol. 2018 Apr;244(5):538-549 [PMID: 29344951]
  122. Mol Cell Biol. 2002 Aug;22(16):5835-45 [PMID: 12138194]
  123. Gynecol Oncol. 2014 Jul;134(1):190-5 [PMID: 24811574]
  124. Anat Sci Int. 2020 Mar;95(2):240-250 [PMID: 31823335]
  125. Front Cell Dev Biol. 2014 Aug 12;2:34 [PMID: 25364741]
  126. Cancer Med. 2017 Feb;6(2):408-415 [PMID: 28109061]
  127. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:322-33 [PMID: 26276546]
  128. Int J Mol Sci. 2021 Feb 06;22(4): [PMID: 33562134]
  129. Cancer Lett. 2020 Nov 1;492:162-173 [PMID: 32858102]
  130. Mol Med Rep. 2015 Oct;12(4):5538-44 [PMID: 26166202]
  131. J Pathol Clin Res. 2021 Mar;7(2):154-164 [PMID: 33416213]
  132. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):213-25 [PMID: 11850228]
  133. Endocrinology. 2005 Feb;146(2):751-9 [PMID: 15528307]
  134. Int J Cancer. 2002 Aug 1;100(4):401-6 [PMID: 12115520]
  135. Ai Zheng. 2006 May;25(5):538-42 [PMID: 16687070]
  136. Curr Top Med Chem. 2019;19(15):1318-1337 [PMID: 31215379]
  137. Cell Commun Signal. 2020 Jun 5;18(1):84 [PMID: 32503542]
  138. Oncol Rep. 2006 May;15(5):1133-6 [PMID: 16596174]
  139. Cancer Res. 2000 Dec 15;60(24):7094-8 [PMID: 11156416]
  140. Obstet Gynecol Int. 2013;2013:537479 [PMID: 23843797]
  141. Oncol Lett. 2018 Nov;16(5):6195-6201 [PMID: 30333884]
  142. Mol Cancer Res. 2021 Jul;19(7):1208-1220 [PMID: 33727343]
  143. Int J Mol Sci. 2019 Jul 30;20(15): [PMID: 31366023]
  144. Oncotarget. 2013 Feb;4(2):316-28 [PMID: 23530112]
  145. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:45-60 [PMID: 34669196]
  146. J Clin Endocrinol Metab. 2004 Dec;89(12):6130-8 [PMID: 15579769]
  147. Cancer Manag Res. 2020 Dec 09;12:12635-12647 [PMID: 33335423]
  148. Mol Med Rep. 2008 May-Jun;1(3):387-90 [PMID: 21479421]
  149. World J Clin Oncol. 2021 Oct 24;12(10):868-881 [PMID: 34733610]
  150. Cancers (Basel). 2020 Sep 07;12(9): [PMID: 32906618]
  151. Maturitas. 2002 Oct 25;43(2):77-85 [PMID: 12385855]
  152. Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7 [PMID: 18599012]
  153. Mol Endocrinol. 2000 Nov;14(11):1882-96 [PMID: 11075819]
  154. Cell Rep. 2014 Jul 24;8(2):460-9 [PMID: 25017071]
  155. Br J Cancer. 2012 May 8;106(10):1682-8 [PMID: 22415229]
  156. Horm Cancer. 2014 Aug;5(4):218-31 [PMID: 24844349]
  157. Int J Oncol. 2015 Jul;47(1):280-6 [PMID: 25964080]
  158. Endocrinology. 2002 Mar;143(3):853-67 [PMID: 11861507]
  159. Mol Endocrinol. 2011 Sep;25(9):1499-512 [PMID: 21700719]
  160. Sci Rep. 2016 May 10;6:25521 [PMID: 27160768]
  161. J Int Med Res. 2020 Sep;48(9):300060520950563 [PMID: 32878530]
  162. Gynecol Oncol. 2007 May;105(2):341-50 [PMID: 17306348]
  163. Front Oncol. 2019 Oct 31;9:1079 [PMID: 31737560]
  164. Int J Mol Sci. 2018 Jul 17;19(7): [PMID: 30018222]
  165. Cancer Biol Med. 2019 Feb;16(1):55-70 [PMID: 31119046]
  166. Anticancer Res. 2002 Jan-Feb;22(1A):139-43 [PMID: 12017277]
  167. Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):37-45 [PMID: 20717823]
  168. Int J Gynecol Cancer. 2008 Jan-Feb;18(1):152-8 [PMID: 17466050]
  169. Oncotarget. 2016 Sep 13;7(37):60038-60052 [PMID: 27527851]
  170. Oncotarget. 2016 May 3;7(18):25712-25 [PMID: 27015552]
  171. Cancer Sci. 2014 Oct;105(10):1307-12 [PMID: 25154549]
  172. Eur J Cancer. 2007 Nov;43(16):2434-44 [PMID: 17911007]
  173. Nature. 2013 May 2;497(7447):67-73 [PMID: 23636398]
  174. Oncol Rep. 2016 Apr;35(4):2391-7 [PMID: 26884084]
  175. Gynecol Endocrinol. 2015;31(8):604-8 [PMID: 26299454]
  176. Mol Cancer Res. 2020 Feb;18(2):204-215 [PMID: 31662448]
  177. Mol Endocrinol. 2005 Mar;19(3):732-48 [PMID: 15528270]
  178. Oncotarget. 2017 Jul 12;8(40):68083-68094 [PMID: 28978098]
  179. Br J Cancer. 2002 Jan 21;86(2):282-4 [PMID: 11870520]
  180. Gynecol Oncol. 2004 Dec;95(3):637-45 [PMID: 15581976]
  181. Mol Cell Endocrinol. 2002 Jun 28;192(1-2):93-104 [PMID: 12088871]
  182. Int J Mol Sci. 2021 Oct 31;22(21): [PMID: 34769256]
  183. Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):557-68 [PMID: 26303083]
  184. Int J Gynecol Cancer. 2017 Jun;27(5):854-862 [PMID: 28498246]
  185. Cancer. 1993 Feb 15;71(4 Suppl):1467-70 [PMID: 8431882]
  186. Int J Clin Exp Pathol. 2018 Feb 01;11(2):577-585 [PMID: 31938143]
  187. J Biol Chem. 2000 Jul 28;275(30):22769-79 [PMID: 10816575]
  188. J Biochem Mol Toxicol. 2021 Nov;35(11):e22905 [PMID: 34463000]
  189. Mol Med Rep. 2008 Nov-Dec;1(6):917-24 [PMID: 21479506]
  190. Oncogene. 2004 Feb 5;23(5):1109-16 [PMID: 14762440]
  191. Am J Pathol. 2012 Jun;180(6):2536-47 [PMID: 22503752]
  192. Oncol Rep. 2015 Mar;33(3):1227-34 [PMID: 25592200]
  193. Gynecol Oncol. 2006 Nov;103(2):417-24 [PMID: 16690106]

Word Cloud

Created with Highcharts 10.0.0ERαECestrogencarcinomaendometrialfactorsignalingpathwayreceptorEndometrialgroupepithelialmalignanciesadenocarcinomasoccurperimenopausalpostmenopausalwomenonecommoncarcinomasfemalereproductivesystemshownoccurrencedevelopmentcloselyassociatedinteractionestradiolE2receptorsERsparticularlykeynucleartranscriptioncarcinogenicinteractionsupstreamdownstreameffectorsco-regulatorsimportantimplicationsproliferationmetastasisinvasioninhibitionapoptosispresentreviewstructureregulationmultipledimensionsdescribedadditionclassicalE2/ERαcrosstalkregulatorselucidatedwelltherapeutictargetingmayprovidenewdirectionclinicalapplicationsfutureRolesαReviewregulator

Similar Articles

Cited By (3)